BiotechTube

Rec 0/0438 1 mg or Rec 0/0438 2 mg + placebo

Phase 1/2Completed
0 watching 0 views this week💤 Quiet
38
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Neurogenic Detrusor Overactivity

Conditions

Neurogenic Detrusor Overactivity

Trial Timeline

Jun 7, 2018 → Mar 27, 2019

NCT ID
NCT03482037

About Rec 0/0438 1 mg or Rec 0/0438 2 mg + placebo

Rec 0/0438 1 mg or Rec 0/0438 2 mg + placebo is a phase 1/2 stage product being developed by Recordati for Neurogenic Detrusor Overactivity. The current trial status is completed. This product is registered under clinical trial identifier NCT03482037. Target conditions include Neurogenic Detrusor Overactivity.

Hype Score Breakdown

Clinical
13
Activity
8
Company
7
Novelty
4
Community
3

Clinical Trials (1)

NCT IDPhaseStatus
NCT03482037Phase 1/2Completed

Competing Products

20 competing products in Neurogenic Detrusor Overactivity

See all competitors
ProductCompanyStageHype Score
MirabegronAstellas PharmaPhase 3
77
Solifenacin succinateAstellas PharmaPhase 3
77
Solifenacin succinateAstellas PharmaPhase 3
77
MirabegronAstellas PharmaPhase 1
33
mirabegronAstellas PharmaPhase 3
77
SAF312 + Placebo to SAF312NovartisPhase 2
52
4 mg Fesoterodine ER tablet from Zwickau + 4 mg fesoterodine ER tablet from Freiburg + 8 mg fesoterodine ER tablet from Zwickau + 8 mg fesoterodine ER tablet from FreiburgPfizerPhase 1
32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mgPfizerPhase 3
76
Fesoterodine BIC SR4 fasted (Treatment A in Part A, Treatment G in Part B) + Fesoterodine BIC SR7 fasted (Treatment B in Part A, Treatment H in Part B) + Fesoterodine BIC SR7 fed (Treatment C in Part A, Treatment F in Part B) + Fesoterodine BIC SR7 on apple sauce (Treatment D in Part A) + Fesoterodine BIC SR4 fed (Treatment E in Part B)PfizerPhase 1
32
Fesoterodine PR 4 mg + Fesoterodine PR 8 mg + Fesoterodine PR 8 mg + Oxybutynin + Fesoterodine PR + Fesoterodine BIC 2 mg + Fesoterodine BIC 4 mgPfizerPhase 3
76
alfuzosin (SL770499)SanofiPhase 3
76
Alfuzosin + PlaceboSanofiPhase 3
76
Droxidopa capsules + Placebo capsulesLundbeckApproved
82
Ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
ampreloxetine + PlaceboTheravance BiopharmaPhase 3
72
TD-9855 + PlaceboTheravance BiopharmaPhase 2
47
ampreloxetineTheravance BiopharmaPhase 3
72
Ampreloxetine <Dose A> + Ampreloxetine <Dose B> + Ampreloxetine Placebo + Moxifloxacin + Moxifloxacin PlaceboTheravance BiopharmaPhase 1
28
AmpreloxetineTheravance BiopharmaPhase 1
28

Other Products from Recordati

Intervention/TreatmentApproved
82
Osilodrostat (Isturisa)Approved
82
Pasireotide + Cabergoline + Pasireotide LARApproved
82
PlenvuApproved
82
SilodosinApproved
82